publication date: Jun. 29, 2018
Drugs & Targets FDA approves Braftovi + Mektovi combination in a melanoma indication
FDA has approved Braftovi capsules in combination with Mektovi tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test.
Braftovi is not indicated for the treatment of patients with wild-type BRAFmelanoma.
The treatment is sponsored by Array BioPharma Inc.
The approval of Braftovi + Mektovi is based on results from the III COLUMBUS trial, which demonstrated the combination doubled median progression-free survival, compared to Zelboraf (vemurafenib), alone (14.9 months versus 7.3 months, respectively [HR (0.54), (95% CI 0.41-0.71), p<0.0001]). Only 5 percent of patients who received Braftovi + Mektovi discontinued treatment due to adverse reactions.
The most common adverse reactions (≥25%) in patients receiving Braftovi + Mektovi were fatigue, nausea, diarrhea, vomiting, abdominal pain, and arthralgia.
In February, the company announced that Braftovi + Mektovi reduced the risk of death compared to treatment with vemurafenib 960 mg daily [hazard ratio (HR) of 0.61, [95% CI 0.47, 0.79, p <0.001] in the planned analysis of overall survival (OS) from the COLUMBUS trial.
Median OS was 33.6 months for patients treated with the combination, compared to 16.9 months for patients treated with … Continue reading FDA approves Braftovi + Mektovi combination in a melanoma indication
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.